Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Of The Analgesic Efficacy And Safety Of Subcutaneous Administration Of Tanezumab In Patients With Osteoarthritis Of The Knee.

Trial Profile

Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Of The Analgesic Efficacy And Safety Of Subcutaneous Administration Of Tanezumab In Patients With Osteoarthritis Of The Knee.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Tanezumab (Primary) ; Tanezumab (Primary)
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Most Recent Events

    • 08 Nov 2017 Results assessing efficacy and tolerability of tanezumab in patients with knee osteoarthritis, were presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 01 May 2012 Actual patient number is 1 according to ClinicalTrials.gov record (Extension trial; NCT01127893).
    • 01 May 2012 Actual patient number is 1 according to ClinicalTrials.gov record (Extension trial; NCT01127893).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top